Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Scientists restore sense of smell in mice through gene therapy

Scientists restore sense of smell in mice through gene therapy

Study identifies mode of death of cone photoreceptor cells in animal model of RP

Study identifies mode of death of cone photoreceptor cells in animal model of RP

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

BioDiem granted European patent for antimicrobial drug

BioDiem granted European patent for antimicrobial drug

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

AAQ chemical temporarily restores vision in blind mice

AAQ chemical temporarily restores vision in blind mice

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

BioDiem presents positive findings of their eye disease drug at international conference

BioDiem presents positive findings of their eye disease drug at international conference

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

BioDiem signs agreement with RMIT to create new non-influenza vaccines

BioDiem signs agreement with RMIT to create new non-influenza vaccines

CDI introduces MyCell Services

CDI introduces MyCell Services

Optogenetic Therapies for Vision workshop to be held on June 1

Optogenetic Therapies for Vision workshop to be held on June 1

New system may help restore vision in eye diseases

New system may help restore vision in eye diseases

Human Gene Therapy highlights new advances in human retinal disease

Human Gene Therapy highlights new advances in human retinal disease

Cellular-level images of the living eye

Cellular-level images of the living eye

Bionic eye helps two blind men see for the first time in 20 years

Bionic eye helps two blind men see for the first time in 20 years

Regenerative medicine research offers hope for the blind

Regenerative medicine research offers hope for the blind

Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women

Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women

Scientists grow rudimentary retina structure from blood cells

Scientists grow rudimentary retina structure from blood cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.